Q32 Bio
QTTB
86 hedge funds and large institutions have $588M invested in Q32 Bio in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 11 reducing their positions, and 6 closing their positions.
1,203% more capital inflows, than outflows
Capital inflows: $167M | Capital outflows: $12.8M
383% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 6
255% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 11
30% more funds holding
Funds holding: 66 → 86 (+20)
7.4% more ownership
Funds ownership: 61.56% → 68.96% (+7.4%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bellevue Group
Kuesnacht,
Switzerland
|
+$30.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.5M |
| 3 |
BlackRock
New York
|
+$14.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13.1M |
| 5 |
Deerfield Management
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.46M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.64M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.42M |
| 4 |
Marshall Wace North America
New York
|
-$1.78M |
| 5 |
Spark Investment Management
New York
|
-$450K |
QTTB Hedge Fund Activity: Q2 2019 in Review
86 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2019, worth a combined $588M — down 8.2% from $641M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new QTTB positions and 6 closed out — a net gain of 23 holders — while 39 added to existing stakes and 11 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $30.6M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $4.46M sold.
- 86 institutional investors held Q32 Bio (QTTB) as of Q2 2019, up from 66 in Q1 2019.
- Funds reported $588M of Q32 Bio stock for Q2 2019, down 8.2% quarter-over-quarter.
- 29 funds opened new Q32 Bio positions in Q2 2019 and 6 closed out, a net change of +23 holders.
- The largest Q32 Bio buyer in Q2 2019 was Bellevue Group, an estimated $30.6M added.
- The largest Q32 Bio seller in Q2 2019 was Sphera Funds Management, an estimated $4.46M sold.
Based on aggregated 13F filings for Q2 2019.